UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinic ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

HPP ranges in severity ... a mineral-targeted form of the missing enzyme called tissue-nonspecific alkaline phosphatase (TNAP). This FDA-approved therapy is based on Millán's decades of research ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three to six times each week.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Researchers have developed a gene therapy that may provide a long-term treatment for hypophosphatasia. Unlike current therapies requiring frequent injections, this approach delivers a single dose to ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Furthermore, the concentrations used are in the nanomolar range, similar to those used in FCS ... dissociate in the presence of their substrates, while alkaline phosphatase does not dissociate in the ...

Background: Data on the association between serum alkaline phosphatase (ALP) levels and clinical outcomes ... This study’s population characteristics were presented as medians (interquartile ranges, ...

For the ranges 1 to 125 fmol/μl and 125 to 2,000 ... and quantification of EGF and IL-8 from 20% serum. An alkaline phosphatase solution was added to a peptide solution containing a 1,938.20 ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maarten J. van der Doelen discussing re-treatment of metastatic castration-resistant ...